[Skip to Content]
[Skip to Content Landing]
Editorial
July 2016

Pathological Diagnosis During Life in Patients With Primary Progressive Aphasia: Seeking the Holy Grail

Author Affiliations
  • 1Neuroscience Research Australia, Randwick, New South Wales, Australia
  • 2Australian Research Council Centre of Excellence in Cognition and its Disorders, Sydney, New South Wales, Australia
  • 3School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia
 

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Neurol. 2016;73(7):788-789. doi:10.1001/jamaneurol.2016.0792

The ability to diagnose the pathology of neurodegenerative diseases in patients during life remains one of the holy grails of behavioral neurology. Considerable progress has been made over the past decade or so. We can now accurately predict the pathology—Alzheimer disease (AD) with plaques and tangles—in patients with progressive amnesia accompanied by attentional and executive deficits and followed, in turn, by aphasic and visuospatial problems. The accuracy of AD diagnoses has also been aided by the advent of ligand-based amyloid positron emission tomographic imaging, although this technique remains extremely expensive and is only available in the developing world and, even there, is not yet available in clinical practice.

×